tiprankstipranks
Trending News
More News >
Ani Pharmaceuticals (ANIP)
:ANIP
Advertisement

ANI Pharmaceuticals (ANIP) AI Stock Analysis

Compare
308 Followers

Top Page

AN

ANI Pharmaceuticals

(NASDAQ:ANIP)

Rating:69Neutral
Price Target:
$73.00
▲(11.98%Upside)
ANI Pharmaceuticals' overall stock score is driven by strong revenue growth and effective cash flow management, as well as positive momentum in technical indicators. The increased guidance and strategic investments highlighted in the earnings call further bolster the outlook. However, ongoing profitability challenges and a negative P/E ratio weigh on the valuation, limiting the overall score.
Positive Factors
Commercial Success
ANIP has established itself as a proven commercial execution success story, evidenced by its delivery on its lead asset, Cortrophin Gel, as well as its generics business unit.
Product Growth
Cortrophin Gel continues to grow well, taking market share from Acthar Gel and driving market expansion, including in label indications which Acthar does not have.
Regulatory Approval
The FDA approved an expanded Iluvien label, adding chronic non-infection uveitis affecting the posterior segment to the current DME indication, which came earlier than expected and reflects continued ANI regulatory execution.
Negative Factors
Legal Dispute
ANIP is currently in a legal dispute regarding the rights to receive a 5% royalty from CGON's cretostimogene sales.
Valuation Concerns
The stock is trading at a valuation more suitable for a pure generics company, despite significant contributions and growth from the rare disease portfolio.

ANI Pharmaceuticals (ANIP) vs. SPDR S&P 500 ETF (SPY)

ANI Pharmaceuticals Business Overview & Revenue Model

Company DescriptionANI Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceuticals. Operating primarily in the United States, the company offers a diverse portfolio that spans several therapeutic areas, including oncology, hormones, and pain management. ANI Pharmaceuticals is known for its robust manufacturing capabilities and commitment to addressing unmet medical needs.
How the Company Makes MoneyANI Pharmaceuticals generates revenue through the production and sale of both branded and generic prescription drugs. The company's revenue streams are primarily driven by its generic pharmaceutical products, which are sold through a network of wholesalers, distributors, and direct sales channels. ANI also earns income from its branded pharmaceuticals business, which includes specialty products that are marketed directly to healthcare professionals. Additionally, the company engages in strategic partnerships and collaborations to enhance its product offerings and expand its market reach, contributing to its overall earnings.

ANI Pharmaceuticals Financial Statement Overview

Summary
ANI Pharmaceuticals demonstrates robust revenue growth and effective cash flow management, which are positive indicators of operational strength. However, persistent net losses and negative return on equity highlight ongoing profitability challenges. The company maintains a stable balance sheet with manageable leverage, but improving profitability metrics will be crucial for enhancing overall financial health.
Income Statement
72
Positive
ANI Pharmaceuticals has shown a strong revenue growth trajectory, with a significant increase from $208 million in 2020 to $674 million in TTM (Trailing-Twelve-Months) 2025. The gross profit margin remains healthy, indicating efficient cost management. However, the company has struggled with profitability, as evidenced by negative net income in recent periods, impacting the net profit margin adversely.
Balance Sheet
65
Positive
The balance sheet reflects a moderate debt-to-equity ratio, indicating a balanced approach to leverage. The equity ratio suggests a reasonable level of equity financing, but the return on equity is negative due to net losses, highlighting challenges in generating shareholder returns. Overall, the balance sheet is stable but shows room for improvement in profitability.
Cash Flow
78
Positive
Cash flow analysis reveals a positive trend in operating cash flow, with a notable increase in free cash flow over the years. The operating cash flow to net income ratio is strong, indicating effective cash generation relative to accounting profits. However, the company has faced significant investing cash outflows, which could impact future liquidity if not managed carefully.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue674.07M614.38M486.82M316.38M216.14M208.47M
Gross Profit385.28M364.17M305.30M177.60M115.53M121.32M
EBITDA76.14M79.15M106.60M48.07M-1.68M29.07M
Net Income-21.05M-18.52M18.78M-47.90M-42.60M-22.55M
Balance Sheet
Total Assets1.29B1.28B904.42M760.09M771.60M461.19M
Cash, Cash Equivalents and Short-Term Investments149.80M151.17M221.12M48.23M100.30M7.86M
Total Debt317.53M624.09M285.67M286.52M287.37M185.69M
Total Liabilities848.96M855.17M446.82M421.55M412.86M265.49M
Stockholders Equity418.62M428.53M457.60M338.54M358.74M195.70M
Cash Flow
Free Cash Flow68.37M47.06M100.45M-47.66M-20.32M-53.05M
Operating Cash Flow80.74M64.02M118.96M-31.20M3.32M15.27M
Investing Cash Flow-433.50M-404.72M-18.51M-15.74M-105.48M-68.32M
Financing Cash Flow274.76M264.94M67.44M-5.13M194.59M-1.44M

ANI Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price65.19
Price Trends
50DMA
63.72
Positive
100DMA
64.12
Positive
200DMA
60.86
Positive
Market Momentum
MACD
0.56
Positive
RSI
53.45
Neutral
STOCH
59.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIP, the sentiment is Positive. The current price of 65.19 is above the 20-day moving average (MA) of 65.07, above the 50-day MA of 63.72, and above the 200-day MA of 60.86, indicating a bullish trend. The MACD of 0.56 indicates Positive momentum. The RSI at 53.45 is Neutral, neither overbought nor oversold. The STOCH value of 59.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANIP.

ANI Pharmaceuticals Risk Analysis

ANI Pharmaceuticals disclosed 75 risk factors in its most recent earnings report. ANI Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ANI Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$1.05B27.0619.23%17.17%-51.97%
72
Outperform
$1.90B30.346.32%11.82%
69
Neutral
$1.41B-5.19%30.26%-173.36%
69
Neutral
$1.03B7.6919.90%8.05%-8.46%
60
Neutral
$1.06B-12.27%3.08%-247.82%
53
Neutral
$1.27B64.45-10.45%24.76%-783.38%
50
Neutral
AU$2.48B3.24-57.47%2.69%36.73%13.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ANIP
ANI Pharmaceuticals
65.19
0.96
1.49%
DVAX
Dynavax
10.74
-0.13
-1.20%
PCRX
Pacira Pharmaceuticals
23.31
1.94
9.08%
SUPN
Supernus Pharmaceuticals
33.96
5.02
17.35%
AMPH
Amphastar Pharmaceuticals
21.95
-17.69
-44.63%
COLL
Collegium Pharmaceutical
32.83
0.88
2.75%

ANI Pharmaceuticals Corporate Events

Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
ANI Pharmaceuticals Highlights Financial Performance Amid Challenges
Neutral
Jun 4, 2025

ANI Pharmaceuticals has highlighted its financial performance indicators, emphasizing the importance of adjusted non-GAAP EBITDA and diluted earnings per share as measures of its operating performance. The company is addressing the impact of recent acquisitions, supply chain disruptions, and regulatory challenges on its operations, while also focusing on maintaining profitability and market acceptance of its products.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

Shareholder MeetingsBusiness Operations and Strategy
ANI Pharmaceuticals Approves Key Proposals at Annual Meeting
Positive
May 23, 2025

ANI Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders on May 22, 2025, where several key proposals were approved. These included amendments to the company’s stock plans and an increase in authorized shares of common stock, reflecting strategic moves to bolster its financial and operational flexibility. The meeting also saw the election of eight directors and the ratification of the appointment of EisnerAmper LLP as the independent registered public accounting firm, indicating a stable governance and financial oversight structure for the upcoming fiscal year.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
ANI Pharmaceuticals Releases May 2025 Financial Presentation
Neutral
May 20, 2025

ANI Pharmaceuticals has released a corporate presentation detailing its financial performance and strategic initiatives as of May 2025. The company emphasizes the importance of adjusted non-GAAP financial measures, such as EBITDA and diluted earnings per share, as key indicators of its operating performance. These metrics exclude various non-cash and one-time expenses to provide a clearer picture of the company’s financial health. The presentation also highlights potential risks and uncertainties, including supply chain disruptions and regulatory challenges, which could impact its operations and financial results.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

Shareholder MeetingsRegulatory Filings and Compliance
ANI Pharmaceuticals Files Proxy for 2025 Meeting
Neutral
May 8, 2025

On April 10, 2025, ANI Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting of shareholders to consider several proposals, including the approval of the Amended and Restated 2022 Stock Incentive Plan. The company issued a Proxy Supplement to clarify that non-shareholder approved inducement grants are included in the share reserve increase proposal. As of March 24, 2025, ANI Pharmaceuticals had 1,177,800 shares available for future grants under the Stock Plan, which is deemed insufficient to attract and retain key talent. The company emphasizes the importance of the Stock Plan in its compensation strategy, aligning with market standards to motivate and retain employees.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025